AIMS: The study evaluated the effectiveness of an 8-week combined group plus individual 12-step facilitative intervention on stimulant drug use and 12-step meeting attendance and service. DESIGN: Multisite randomized controlled trial, with assessments at baseline, mid-treatment, end of treatment, and 3- and 6-month post-randomization follow-ups (FUs). SETTING: Intensive outpatient substance treatment programs. PARTICIPANTS: Individuals with stimulant use disorders (n = 471) randomly assigned to treatment as usual (TAU) or TAU into which the Stimulant Abuser Groups to Engage in 12-Step (STAGE-12) intervention was integrated. MEASUREMENTS: Urinalysis and self-reports of substance use and 12-step attendance and activities. INTERVENTION: Group sessions focused on increasing acceptance of 12-step principles; individual sessions incorporated an intensive referral procedure connecting participants to 12-step volunteers. FINDINGS: Compared with TAU, STAGE-12 participants had significantly greater odds of self-reported stimulant abstinence during the active 8-week treatment phase; however, among those who had not achieved abstinence during this period, STAGE-12 participants had more days of use. STAGE-12 participants had lower Addiction Severity Index Drug Composite scores at and a significant reduction from baseline to the 3-month FU, attended 12-step meetings on a greater number of days during the early phase of active treatment, engaged in more other types of 12-step activities throughout the active treatment phase and the entire FU period, and had more days of self-reported service at meetings from mid-treatment through the 6-month FU. CONCLUSIONS: The present findings are mixed with respect to the impact of integrating the STAGE-12 intervention into intensive outpatient drug treatment compared with TAU on stimulant drug use. However, the results more clearly indicate that individuals in STAGE-12 had higher rates of 12-step meeting attendance and were engaged in more related activities throughout both the active treatment phase and the entire 6-month FU period than did those in TAU.
RCT Entities:
AIMS: The study evaluated the effectiveness of an 8-week combined group plus individual 12-step facilitative intervention on stimulant drug use and 12-step meeting attendance and service. DESIGN: Multisite randomized controlled trial, with assessments at baseline, mid-treatment, end of treatment, and 3- and 6-month post-randomization follow-ups (FUs). SETTING: Intensive outpatient substance treatment programs. PARTICIPANTS: Individuals with stimulant use disorders (n = 471) randomly assigned to treatment as usual (TAU) or TAU into which the Stimulant Abuser Groups to Engage in 12-Step (STAGE-12) intervention was integrated. MEASUREMENTS: Urinalysis and self-reports of substance use and 12-step attendance and activities. INTERVENTION: Group sessions focused on increasing acceptance of 12-step principles; individual sessions incorporated an intensive referral procedure connecting participants to 12-step volunteers. FINDINGS: Compared with TAU, STAGE-12 participants had significantly greater odds of self-reported stimulant abstinence during the active 8-week treatment phase; however, among those who had not achieved abstinence during this period, STAGE-12 participants had more days of use. STAGE-12 participants had lower Addiction Severity Index Drug Composite scores at and a significant reduction from baseline to the 3-month FU, attended 12-step meetings on a greater number of days during the early phase of active treatment, engaged in more other types of 12-step activities throughout the active treatment phase and the entire FU period, and had more days of self-reported service at meetings from mid-treatment through the 6-month FU. CONCLUSIONS: The present findings are mixed with respect to the impact of integrating the STAGE-12 intervention into intensive outpatient drug treatment compared with TAU on stimulant drug use. However, the results more clearly indicate that individuals in STAGE-12 had higher rates of 12-step meeting attendance and were engaged in more related activities throughout both the active treatment phase and the entire 6-month FU period than did those in TAU.
Authors: Mary Hatch-Maillette; Elizabeth A Wells; Suzanne R Doyle; Gregory S Brigham; Dennis Daley; Jessica DiCenzo; Dennis Donovan; Sharon Garrett; Viviana E Horigian; Lindsay Jenkins; Therese Killeen; Mandy Owens; Harold I Perl Journal: J Subst Abuse Treat Date: 2016-06-16
Authors: Elizabeth A Wells; Dennis M Donovan; Dennis C Daley; Suzanne R Doyle; Greg Brigham; Sharon B Garrett; Michelle H Ingalsbe; Mary A Hatch-Maillette; Harold I Perl; Robrina Walker Journal: J Subst Abuse Treat Date: 2014-06-14
Authors: Morgan M Medlock; David H Rosmarin; Hilary S Connery; Margaret L Griffin; Roger D Weiss; Sterling L Karakula; R Kathryn McHugh Journal: Am J Addict Date: 2017-08-24
Authors: Barbara K Campbell; Allison Buti; Holly E Fussell; Priya Srikanth; Dennis McCarty; Joseph R Guydish Journal: Am J Drug Alcohol Abuse Date: 2013-07-09 Impact factor: 3.829
Authors: Joseph Guydish; Barbara K Campbell; Jennifer K Manuel; Kevin L Delucchi; Thao Le; K Michelle Peavy; Dennis McCarty Journal: Drug Alcohol Depend Date: 2013-11-04 Impact factor: 4.492
Authors: Bryon Adinoff; Thomas J Carmody; Robrina Walker; Dennis M Donovan; Gregory S Brigham; Theresa M Winhusen Journal: Am J Drug Alcohol Abuse Date: 2016-01-08 Impact factor: 3.829